Clinical trials: Breast Adenocarcinoma
Male Breast Cancer, Recurrent Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
Vaccines may make the body build an immune response to kill tumor cells. This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic breast cancer.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00071942
- Testing
- recombinant vaccinia-MUC1 vaccine, recombinant vaccinia-TRICOM vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Breast Cancer
Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01132560
- Testing
- RNA analysis, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 500 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Breast Cancer
Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)
In this research study, the investigators are testing a new type of breast camera, called Molecular Breast Imaging, to see if it can find tumors in the subject's breast.
- Trial name
- NCT00890994
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Neoplasms, Breast Neoplasms
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Dose escalation part: to determine the highest dose of alpelisib administered on a daily basis when given in combination with daily everolimus or in combination with daily everolimus and exemestane.
- Conditions
- Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
- Trial name
- NCT02077933
- Testing
- alpelisib, everolimus, exemestane
- Where
- 22 sites in United States, France and 7 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Breast Neoplasms
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
- Conditions
- Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell
- Trial name
- NCT00043368
- Testing
- PF-3512676
- Where
- 32 sites in United States, Germany
- Volunteers
- 31 people
- Sponsor
- Pfizer
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Breast Neoplasms, Carcinoma, Ductal
Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC
Cardiac perfusion changes have been seen after whole breast / chest wall irradiation for breast cancer. The Active Breathing Coordinator (ABC) device theoretically decreases radiation exposure to the heart during radiation for…
- Conditions
- Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
- Trial name
- NCT00321048
- Testing
- Active Breathing Coordinator
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DCIS, Stage 0 Breast Cancer
The PREDICT Registry:
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions.
- Conditions
- DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
- Trial name
- NCT03448926
- Testing
- Treatment recommendation surveys, 7-gene biosignature
- Where
- 30 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- PreludeDx
Prostate Cancer, Breast Cancer
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
This pilot clinical trial studies how well using the internet to collect symptoms and the ability to carry out daily activities works in patients with enrolled on Cancer and Leukemia Group B (CALGB) studies.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- NCT00417040
- Testing
- internet-based intervention, assessment of therapy complications, Questionnaire Administration
- Where
- 95 sites in United States
- Volunteers
- 325 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Cognitive Ability, General
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
RATIONALE: Radiation therapy uses high-energy x rays to kill tumor cells. Radiation therapy may cause skin reactions when patients are exposed to high-energy x rays.
- Conditions
- Breast Cancer, Cognitive Ability, General, Fatigue, Pain
- Trial name
- NCT01407770
- Testing
- DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Wake Forest University Health Sciences
Ductal Breast Carcinoma, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy.
- Conditions
- Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma
- Trial name
- NCT03414970
- Testing
- Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment
- Where
- 859 sites in United States, Canada
- Volunteers
- 898 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Renal Cell Carcinoma
Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
Everolimus shows a large interpatient variability with fixed dose administration. These very different exposure levels between individuals can result in supratherapeutic or subtherapeutic exposure levels and consequently in over…
- Trial name
- SPOT (NCT02809404)
- Testing
- Everolimus
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Radboud University Medical Center
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Bladder Carcinoma, Breast Carcinoma
The Vanguard Study: Testing a New Way to Screen for Cancer
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial.
- Conditions
- Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma
- Trial name
- NCT06995898
- Testing
- Biospecimen Collection, Device Usage, Electronic Health Record Review
- Where
- 45 sites in United States
- Volunteers
- 24,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Urachal Cancer, Advanced Solid Tumor Cancer
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent.
- Conditions
- Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates
- Trial name
- NCT07309770
- Testing
- SHR-A1811, Trastuzumab Rezetecan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sheng Zhang